FMP

FMP

Enter

IDXG - Interpace Bioscience...

photo-url-https://images.financialmodelingprep.com/symbol/IDXG.png

Interpace Biosciences, Inc.

IDXG

PNK

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

0.89 USD

-0.03 (-3.37%)

Operating Data

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

132.51M

170.36M

310.02M

363.14M

414.29M

561.12M

760M

1.03B

1.39B

1.89B

Revenue %

-

28.57

81.98

17.13

14.09

35.44

35.44

35.44

35.44

Ebitda

-39.8M

-38.71M

-130.92M

-110.34M

-71.19M

-159.98M

-216.68M

-293.48M

-397.5M

-538.38M

Ebitda %

-30.03

-22.72

-42.23

-30.39

-17.18

-28.51

-28.51

-28.51

-28.51

Ebit

-48.31M

-46.92M

-173.53M

-157.72M

-116.36M

-214.91M

-291.07M

-394.23M

-533.96M

-723.2M

Ebit %

-36.46

-27.54

-55.97

-43.43

-28.09

-38.3

-38.3

-38.3

-38.3

Depreciation

8.52M

8.21M

42.61M

47.38M

45.16M

54.92M

74.39M

100.75M

136.46M

184.82M

Depreciation %

6.43

4.82

13.74

13.05

10.9

9.79

9.79

9.79

9.79

EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep